BioSpace News Archive

Job Trends

Life Sciences R&D, Manufacturing Talent Becoming More Difficult to Find: Report

Securing top talent in research and development and manufacturing will remain challenging for life sciences companies in 2024, according to a new report by CBRE.

June 6, 2024
·
3 min read
·
Greg Slabodkin
Policy

Moderna’s mRNA Candidate Joins FDA’s Accelerator Program for Rare Diseases

Moderna on Thursday said its investigational mRNA-based therapy for methylmalonic acidemia has been selected for the FDA’s accelerator program for rare diseases, dubbed START.

June 6, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Amgen Phase III Win Positions Uplizna for Label Expansion in Rare Autoimmune Disease

Amgen’s CD19-directed antibody Uplizna in a late-stage study showed it can suppress the risk of flares by nearly 90% in patients with IgG4-related disease, the company announced Wednesday.

June 6, 2024
·
2 min read
·
Tristan Manalac
Deals

Telix Targets $200M IPO in Hot Radiopharma Market as Biotech Nasdaq Offerings Slow

Telix Pharmaceuticals is looking to cash in on radiopharmaceuticals, which have emerged as one of the hottest spaces in oncology, with an initial public offering to help support its pipeline of targeted radiation products.

June 6, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Novo’s Ozempic, Wegovy to Face Stiff Generic Competition in China: Reuters

Novo Nordisk will face strong generic competition from at least 15 companies in China for its blockbuster GLP-1 receptor agonist products Wegovy and Ozempic, according to Reuters.

June 6, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Structure Looks to Raise $476M in Upsized Public Offering After Positive Phase II Weight Loss Data

Structure Therapeutics is offering over nine million shares on the heels of mid-stage data for its oral GLP-1 receptor agonist, which showed weight loss of 6.2% in overweight or obese patients.

June 6, 2024
·
2 min read
·
Tyler Patchen
Drug Development

Boehringer, Zealand’s GLP-1 MASH Data ‘Unintentionally’ Published by Medical Congress Website

Zealand Pharma said on Thursday that partner Boehringer Ingelheim will present the results from the study on Friday at the European Association of the Study of Liver Congress.

June 6, 2024
·
2 min read
·
Nick Paul Taylor
ITM Raises €188m to Enhance Radiopharmaceutical Pipeline and to Strengthen Leading Position in Medical Radioisotope Manufacturing

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced an equity investment of €188 million led by Temasek with participation from funds managed by BlackRock, Qatar Investment Authority, ATHOS and Carbyne.

June 6, 2024
·
7 min read
Drug Development

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

Sagimet Biosciences Inc. presented positive data from its FASCINATE-2 Phase 2b clinical trial of denifanstat versus placebo in biopsy-confirmed metabolic dysfunction-associated steatohepatitis patients at the European Association for the Study of the Liver Congress being held in Milan, Italy.

June 6, 2024
·
10 min read
Drug Development

Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL

Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL

June 6, 2024
·
6 min read